|Mr. Edward H. Myles M.B.A., MBA||CFO, COO & Treasurer||615.87k||N/A||1972|
|Dr. Jay T. Backstrom M.D., M.P.H.||Pres, CEO & Director||N/A||N/A||1955|
|Ms. Catherine Hu||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Junlin Ho J.D.||Gen. Counsel & Corp. Sec.||N/A||N/A||1979|
|Ms. Caryn Parlavecchio||Chief HR Officer||N/A||N/A||1972|
|Ms. Lisa Amaya Price||Sr. VP of HR||N/A||N/A||N/A|
|Dr. George G. Nomikos M.D., Ph.D.||Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area||N/A||N/A||N/A|
|Ms. Erin Moore||Sr. VP of Fin.||N/A||N/A||1975|
|Mr. Ryan Iarrobino||Sr. VP of Clinical Devel. & Operations||N/A||N/A||N/A|
|Dr. Jing L. Marantz M.B.A., M.D., Ph.D.||Chief Medical Officer||N/A||N/A||1965|
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Scholar Rock Holding Corporation’s ISS Governance QualityScore as of November 28, 2022 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 8.